drugset / Trial / NCT06470373
A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration
RandomizedParallel-groupDouble-blindTreatment
Summary
This clinical study is designed to demonstrate the equivalence of the two Investigational Products by comparing the efficacy, safety, tolerability and immunogenicity of RBS-001 and Eylea® in subjects with Neovascular age-related macular degeneration.
Timeline
- Start
- 2025-07
- Primary completion
- 2026-09
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 0.05 ml | Intravitreal |
| Comparator | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Comparator | RBS-001 | Unknown | 0.05 ml | Intravitreal |
| Comparator | RBS-001 | Unknown | 2 mg | Intravitreal |